

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. – 8. (canceled)

9. (original) A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 154 of SEQ ID NO:1.

10. (original) A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 174 of SEQ ID NO:2.

11. (original) A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 138 of SEQ ID NO:3.

12. (original) A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 175 of SEQ ID NO:4.

13. (original) A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 226 of SEQ ID NO:5.

14. (original) A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 387 of SEQ ID NO:6.

15. (original) A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 438 of SEQ ID NO:7.

16. – 18. (canceled)

19. (new) A chimeric fusion protein comprising an amino terminus and a carboxyl terminus, wherein the protein comprises, in order, starting at the amino terminus, insulin chain B, insulin chain C and human GAD 65 peptides 115-127, 247-286, and 473-519, wherein the insulin chain B and the at least one human GAD 65 peptide (s) are covalently linked and the chimeric fusion

protein is capable of eliciting a human T cell response to insulin chain B and to each of the GAD 65 peptides.